section name header

Pronunciation

ri-MAN-ti-deen

Classifications

Therapeutic Classification: antivirals

Indications

REMS


Unlabeled Use:
  • Treatment of influenza A infection in children.

Action

  • Diminishes replication of influenza A virus by inhibiting uncoating of the virus.
Therapeutic effects:
  • When given prophylactically, prevents infection with influenza A virus. When administered within 48 hr of onset of infections, decreases the duration of fever and other associated symptoms.

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver; <25% excreted unchanged in urine.

Half-Life: 25 hr (range 13–65 hr).

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POrapid6 hrN/A





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

EENT: tinnitus

GI: abdominal pain, anorexia, diarrhea, dry mouth, dyspepsia, nausea, vomiting

Neuro: agitation, dizziness, fatigue, headache, impaired concentration, insomnia, mental depression, SEIZURES

Resp: dyspnea

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Flumadine